Significant progress has been made in modern medicine, but these developments frequently present difficult moral and financial issues. A potent illustration of both scientific achievement and social injustice is the gene therapy Elevidys, which was created to treat Duchenne Muscular Dystrophy (DMD). Although the treatment gives families hope, it also raises significant questions regarding long-term safety, affordability, and accessibility.
One of the biggest challenges with Elevidys is how expensive it is. Gene therapies are among the most costly medical procedures ever created — with costs per patient ranging from two to three million dollars. Most families cannot afford the therapy due to its high cost, particularly in low- and middle-income nations. In regions where health insurance coverage is limited, paying for such treatment could result in severe financial hardship or lifetime debt. As a result, only the wealthy have access to life-saving treatments, which leads to growing disparities in healthcare systems around the world.
Insurance companies are also faced with uncertainty when determining whether to cover gene therapies. Long-term data regarding the safety and efficacy of these treatments is still scarce because they are relatively new. This reluctance further limits accessibility for many patients who depend on financial assistance to pay for medical care.
Another major concern is the experimental nature of the therapy itself. Elevidys does not cure DMD — rather, it helps maintain motor function and slows the progression of the disease. Safety warnings have also been issued in response to uncommon but significant side effects, such as treatment-related liver failure. The significance of careful patient selection and ongoing monitoring is highlighted by such incidents.
Gene therapy compels society to address more general ethical issues. Should only those who can afford them have access to life-saving treatments? How can healthcare systems and governments guarantee that everyone has access to cutting-edge medical technology? In the end, future gene therapy success will rely on both scientific advancement and the creation of just laws that guarantee treatments are available to everyone who requires them.